To develop the platform, Gentag has utilised immunoassay technology and made it wireless and compatible with Near Field Communication (NFC) technology.
Gentag said the platform allows consumers to use their cell phones as diagnostic tools to instantly test for common medical conditions, pathogens and allergens.
The new technology is expected to broadly impact major women’s health markets, including ovulation, fertility, and PROM (labor); the men’s health market, including a urine-based prostate cancer test (PCADM-1); and tests for common food allergens.
Gentag founder John Peeters said the technology breakthrough will enable much more rapid diagnoses for diseases and make diagnostics more accessible and affordable for more people worldwide.
